epigallocatechin gallate has been researched along with Experimental Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Della Via, FI; Ferro, KP; Franchi Junior, GC; Rego, EM; Saad, STO; Salazar-Terreros, MJ; Santos, I; Shiraishi, RN; Torello, CO | 1 |
| Hayakawa, S; Matsui, T; Shimizu, K; Suzuki, Y; Suzuki-Karasaki, M; Yamaki, M; Yamashita, K; Yoshimaru, T | 1 |
2 other study(ies) available for epigallocatechin gallate and Experimental Leukemia
| Article | Year |
|---|---|
(-)-Epigallocatechin-3-gallate induces apoptosis and differentiation in leukaemia by targeting reactive oxygen species and PIN1.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; bcl-Associated Death Protein; Catechin; Cell Differentiation; Humans; Leukemia, Experimental; Leukemia, Promyelocytic, Acute; Mice, Transgenic; NIMA-Interacting Peptidylprolyl Isomerase; Reactive Oxygen Species; Retinoic Acid Receptor alpha; Spleen | 2021 |
Epigallocatechin gallate inhibits histamine release from rat basophilic leukemia (RBL-2H3) cells: role of tyrosine phosphorylation pathway.
Topics: Animals; Antineoplastic Agents; Catechin; Histamine Release; Leukemia, Basophilic, Acute; Leukemia, Experimental; Mast Cells; Phosphorylation; Rats; Signal Transduction; Tumor Cells, Cultured; Tyrosine | 2000 |